Add this topic to your myFT Digest for news straight to your inbox
Heartburn medication made by Sanofi of France has been linked to cancer-causing impurity
Groups join effort to repurpose existing remedies in fight against global pandemic
French drugmaker says coronavirus has put national sovereignty of healthcare ‘sharply into focus’
Chief to float 70% stake in standalone group to create ‘new industry champion’
Pharma company’s use of algorithms marks fast-growing trend in big digitally-savvy markets including India
New chief Paul Hudson aims to narrow research focus and cut costs
French drugmaker has diagnosed oncology and rare diseases as potential areas of growth
Drugs group unveils tighter strategic vision as Merck also acquires oncology biotech
Pharma giant puts $2.5n price on unprofitable San Diego-based company
Thank you ASA, for helping to promote our own Fyre Festival.
Why the pharma industry has more to gain than lose
Paul Hudson, who ran Swiss group’s pharmaceuticals business, will take over in September
Officials say fear of vaccines after Dengvaxia scandal is main reason for measles epidemic
Some companies pledge to lower costs if government reforms rebate system
Politicians to grill pharma executives over what is fast becoming a key election issue
Drugmakers lower cost of anti-cholesterol drug amid slow take-up and political pressure
French pharma group says ‘strategic transformation has brought fruit’
Cost increase for essential medicine comes as drugmakers face political pressure
As well as reducing emissions, the industry seeks to develop drugs as disease patterns shift
Sanofi and Novartis join list of pharma groups with rising concerns over no-deal Brexit
Despite focus on rare diseases, group has not mapped out a very prosperous future
Although racism is not a consequence of taking the drug, doctors warn about other dangers
Sales of Praluent have been hurt by the campaign to limit US pharmaceuticals costs
International Edition